Dallas, Texas 02/07/2014 (FINANCIALSTRENDS) – In a recent program that was broadcasted on Canadian TV the technology used by StemCells Inc (NASDAQ:STEM) was shown by Dr. Michael Fehlings. He discussed about the importance of the technology for the treatment of Spinal Cord injury. Recently company’s CEO Mr. Martin McGlynn also announced that the company is deeply committed towards protecting the interest of shareholders and he is going to give presentation at the Alliance for Regenerative Medicine’s Investor Conference on 26th March, 2014.
If you wish to see the live webcast of the conference then you can log on the official website of the company. As the company is consistently moving ahead in the field of stem cell therapy there are many investment analysts who are quite bullish about the StemCells Inc. and have maintained a strong buy rating on the stock. As per them those who have got along term horizon of 1 to 2 years will definitely reap some good rewards with excellent returns.
An overview of the Company
StemCells Inc (NASDAQ:STEM) is a company that deals in research, development and commercialization of cell based therapeutics and special tools that are quite useful in all the stem cell based research and drug discoveries. Currently the company is conducting a Phase 1 and 2 clinical trials in the field of chronic spinal cord injury. The facility where the company is conducting a trail is situated in Switzerland, Canada and the United States of America.
Recently the company has also started conducting phase 1 and 2 trials in dry age-related macular degeneration in the United States of America. Apart from all such clinical trials the company is also doing marketing of various stem cell research products that includes media and reagents under the SC Proven(R) brand. You can gain in-depth information about the company from its official website that is stemcellsinc.com.